Mesenchymal Stem Cells Ameliorate DSS-Induced Experimental Colitis by Modulating the Gut Microbiota and MUC-1 Pathway
Han Wang,Yang Sun,Feng-Jun Xiao,Xia Zhao,Wei-Yuan Zhang,Yu-Jun Xia,Li-Sheng Wang
DOI: https://doi.org/10.2147/jir.s402592
IF: 4.5
2023-05-11
Journal of Inflammation Research
Abstract:Han Wang, 1, 2, &ast Yang Sun, 1, 2, &ast Feng-Jun Xiao, 3, &ast Xia Zhao, 2, 4 Wei-Yuan Zhang, 1, 2 Yu-Jun Xia, 1 Li-Sheng Wang 1, 2 1 School of Basic Medicine, Qingdao University, Qingdao, 266071, People's Republic of China; 2 Laboratory of Molecular Diagnosis and Regenerative Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People's Republic of China; 3 Beijing Institute of Radiation Medicine, Beijing, 100850, People's Republic of China; 4 Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li-Sheng Wang, Laboratory of Molecular Diagnosis and Regenerative Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People's Republic of China, Email Yu-Jun Xia, School of Basic Medicine, Qingdao University, Qingdao, 266071, People's Republic of China, Email Purpose: Mesenchymal stem cells (MSCs) have become novel therapeutic agents for the treatment of inflammatory bowel diseases (IBDs). However, the precise cellular and molecular mechanisms by which MSCs restore intestinal tissue homeostasis and repair the epithelial barrier have not been well elucidated. This study aimed to investigate the therapeutic effects and possible mechanisms of human MSCs in the treatment of experimental colitis. Methods: We performed an integrative transcriptomic, proteomic, untargeted metabolomics, and gut microbiota analyses in a dextran sulfate sodium (DSS)-induced IBD mouse model. The cell viability of IEC-6 cells was determined by Cell Counting Kit-8 (CCK-8) assay. The expression of MUC-1 and ferroptosis-related genes were determined by immunohistochemical staining, Western blot, and real-time quantitative polymerase chain reaction (RT-qPCR). Results: Mice treated with MSCs showed notable amelioration in the severity of DSS-induced colitis, which was associated with reduced levels of proinflammatory cytokines and restoration of the lymphocyte subpopulation balance. Treatment with MSC restored the gut microbiota and altered their metabolites in DSS-induced IBD mice. The 16s rDNA sequencing showed that treatment with MSC modulated the composition of probiotics, including the upregulation of the contents of Firmicutes, Lactobacillus, Blautia, Clostridia, and Helicobacter bacteria in mouse colons. Protein proteomics and transcriptome analyses revealed that pathways related to cell immune responses, including inflammatory cytokines, were suppressed in the MSC group. The ferroptosis-related gene, MUC-1 , was significantly upregulated in the MSC-treated group. MUC-1 -inhibition experiments indicated that MUC-1 was essential for epithelial cell growth. Through overexpression of MUC-1 , it showed that upregulation of SLC7A11 and GPX4 , and downregulation of ACSL4 in erastin and RSL3-treated IEC-6 cells, respectively. Conclusion: This study described a mechanism by which treatment with MSCs ameliorated the severity of DSS-induced colitis by modulating the gut microbiota, immune response, and the MUC-1 pathway. Keywords: inflammatory bowel disease, mesenchymal stem cells, gut microbiota, MUC-1, multi-omics Mesenchymal stem cells (MSCs) have been approved as novel therapeutic agents for the treatment of inflammatory bowel diseases (IBDs) in clinical trials, including ulcerative colitis and Crohn's disease. 1 MSCs, which are well-known immunomodulatory agents, are effective agents for promoting tissue repair and regeneration. 2 Systemic administration of MSCs derived from various resources, such as bone marrow, adipose tissues, and umbilical cord (UC), shows beneficial effects in the treatment of IBD. Allogenic adipose-derived MSCs, which have long-term efficacy and safety for use in complex perianal fistulas in patients with Crohn's disease, have been approved in Europe. 3 Moreover, MSCs derived from umbilical cord and bone marrow have been investigated in clinical trials for treatment of IBD. 4,5 Preclinical and clinical studies have validated the benefits of MSC treatment for IBD by maintaining intestinal integrity and tissue repair. 1,6 The clinical outcomes of MSCs derived from various resources will be investigated in further clinical trials. Treatment with MSC ameliorates colitis inflammation by repairing the intestinal epithelial barrier injury and regulating immune responses. Regulation of the anti-inflammatory pathways and cytok -Abstract Truncated-
immunology